Wedbush Morgan Maintains a 'Buy' on Poniard Pharmaceuticals (PARD); Renewed Interest in Emerging Pharma Sector - Raises Price Target
Tweet Send to a Friend
Wedbush Morgan maintains a 'Buy' on Poniard Pharmaceuticals Inc. (Nasdaq: PARD), raises price target from $6 to $15.
Wedbush analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wedbush analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
